Parsons Capital Management Inc. RI trimmed its position in shares of Waters Co. (NYSE:WAT) by 0.6% in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 10,085 shares of the medical instruments supplier’s stock after selling 60 shares during the quarter. Parsons Capital Management Inc. RI’s holdings in Waters were worth $2,171,000 as of its most recent SEC filing.
A number of other institutional investors also recently added to or reduced their stakes in WAT. Anchor Capital Advisors LLC acquired a new stake in Waters during the 2nd quarter worth $10,790,000. Amica Retiree Medical Trust acquired a new stake in Waters during the 2nd quarter worth $69,000. DekaBank Deutsche Girozentrale boosted its stake in Waters by 4.7% during the 2nd quarter. DekaBank Deutsche Girozentrale now owns 50,073 shares of the medical instruments supplier’s stock worth $10,747,000 after purchasing an additional 2,256 shares during the last quarter. Stanley Laman Group Ltd. boosted its stake in Waters by 0.4% during the 2nd quarter. Stanley Laman Group Ltd. now owns 21,805 shares of the medical instruments supplier’s stock worth $4,693,000 after purchasing an additional 87 shares during the last quarter. Finally, Amica Mutual Insurance Co. acquired a new stake in Waters during the 2nd quarter worth $434,000. 96.08% of the stock is currently owned by hedge funds and other institutional investors.
Shares of WAT stock traded up $2.18 on Thursday, hitting $202.22. 8,604 shares of the stock traded hands, compared to its average volume of 581,731. The company’s 50-day moving average price is $214.55. The company has a quick ratio of 2.07, a current ratio of 2.65 and a debt-to-equity ratio of 2.00. The company has a market capitalization of $13.35 billion, a PE ratio of 24.36, a PEG ratio of 2.30 and a beta of 1.07. Waters Co. has a twelve month low of $167.93 and a twelve month high of $255.21.
Several brokerages have issued reports on WAT. UBS Group lowered their target price on shares of Waters from $248.00 to $230.00 and set a “neutral” rating on the stock in a research note on Wednesday, April 24th. Cleveland Research cut shares of Waters from a “neutral” rating to an “underperform” rating in a research note on Wednesday, June 12th. ValuEngine cut shares of Waters from a “buy” rating to a “hold” rating in a research note on Thursday, August 1st. Barclays lowered their price target on shares of Waters from $218.00 to $210.00 and set an “equal weight” rating on the stock in a research report on Wednesday, April 24th. Finally, Zacks Investment Research raised shares of Waters from a “sell” rating to a “hold” rating and set a $217.00 price target on the stock in a research report on Wednesday, May 22nd. Five research analysts have rated the stock with a sell rating, eight have assigned a hold rating and one has given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and a consensus target price of $210.54.
Waters Company Profile
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans.
Read More: Why do companies engage in swaps?
Receive News & Ratings for Waters Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Waters and related companies with MarketBeat.com's FREE daily email newsletter.